Citations

Clear

219 citation(s) found for "Do, Ron".

Assessing the Learning Curve of the Vertebral Body Tethering in Idiopathic Scoliosis: A Multicenter Analysis
Vollano, Nicholas , Ezeonu, Samuel , Smit, Kevin , Parent, Stéfan, Miyanji, Firoz , Cho, Robert H. , Rodriguez-Olaverri, Juan Carlos, Group, on behalf of the Pediatric Spine Study, Larson, A. Noelle , El‐Hawary, Ron , Guillaume, Tenner J. , Truong, Walter H. , Cheung, Kmc , Group, on behalf of the Pediatric Spine Study

Mayo Clinic

Journal of Pediatric Orthopaedics | November 13, 2025 | Volume: 46 | Issue: 3 | Pages: 147-153

10.1097/bpo.0000000000003150 | PMID 41230630 Get It

Background: Anterior vertebral body tethering (AVBT) is a promising fusionless alternative for treating idiopathic scoliosis; however, limited data exist on the learning curve for this procedure. Previous studies are limited by single-center and short-term complication data. This multicenter study assesses the learning curve by evaluating improvements in operative characteristics over time and radiographic measurements up to 2 years postoperatively. Methods: As recorded from a multicenter registry, surgeons with ≥10 index AVBT procedures for patients with idiopathic scoliosis aged 16 years and below were included. Relationships between case number and multiple surgical variables were determined using Pearson correlation and linear regression testing. For identification of an inflection point, consecutive cases were plotted against operative time per level and fitted with a locally weighted scatterplot smoothing curve. Independent samples t test and χ 2 test were used to compare outcomes between cases before and after the inflection point. Outcomes of interest included demographic, surgical, and radiographic information at the baseline, immediate postoperative, and 2-year timepointswhere available. Results: Eight surgeons and 325 index AVBT patients met the inclusion criteria. Inverse relationships were identified between case number and estimated blood loss, operative time, anesthesia time, and fluoroscopic time per level ( P < 0.005). The inflection point was identified at 15 cases. Operative time, anesthesia time, and fluoroscopy time per level were greater in the first 15 cases compared with those after ( P < 0.05). There were no significant differences in demographic variables, intraoperative complications, or length of stay between the early and late cases. Greater correction in the major coronal curve, minor coronal curve, and coronal balance occurred in the cases performed after the inflection point ( P < 0.05). Conclusions: AVBT is a safe alternative to posterior spinal fusion and demonstrates a predictable improvement in surgical performance over time. Large improvements can be expected during the first 15 AVBT cases performed with minimal differences in complications. Level of Evidence: Level III.
Chimeric antigen receptor T‐cell therapy for high‐grade B‐cell lymphoma NOS
Hossain, Nasheed , Ahn, Kwang Woo , Patel, Jinalben , Lian, Qinghua, Abid, Muhammad Bilal , Nughmush, Ahmed Al, Bi, Xia , Hashmi, Shahrukh K. , Hilal, Talal , Modi, Dipenkumar , Rizzieri, David A. , Steinberg, Amir , Vij, Ravi, Herrera, Alex F. , Hossain, Nasheed M , Abid, Muhammad Bilal , Bacher, Ulrike , Hilal, Talal , Modi, Dipenkumar , Hamadani, Mehdi , Herrera, Alex F , Husnain, Muhammad , Khimani, Farhad , Maziarz, Richard Thomas , Ram, Ron , Sica, Roberto Alejandro , Shadman, Mazyar , Turtle, Cameron J. , Hamadani, Mehdi

Mayo Clinic

British Journal of Haematology | July 22, 2025 | Volume: 207 | Issue: 3 | Pages: 1011-1018

10.1111/bjh.70020 | PMID 40693472 Get It

Summary CD19 chimeric antigen receptor T‐cell (CAR‐T) therapy is a pivotal part of the treatment algorithm for large B‐cell lymphoma (LBCL) in the second‐ and third‐line settings based on numerous clinical trials. However, these studies included very few patients with a diagnosis of high‐grade B‐cell lymphoma, not otherwise specified (HGBCL‐NOS) and it is unclear if outcomes are similar to those observed with more common LBCL histologies. Using the Center for International Blood and Marrow Transplant Research (CIBMTR) registry, we identified 111 HGBCL‐NOS patients who received CAR‐T therapy. The cytokine release syndrome (CRS) rate was 74% (7.7% grade 3+), median onset was 4 days (1–17) and immune effector cell‐associated neurotoxicity syndrome rate was 45.2% (22.6% grade 3+), median onset was 7 days (1–17). At 2 years post‐CAR‐T infusion, the probability of overall survival and progression‐free survival were 41.6% and 28.7% respectively. The 2‐year non‐relapse mortality and relapse/progression were 3.1% (95% confidence interval [CI]: 0.6–7.6) and 68.1% (95% CI: 57.9–77.6) respectively. Our analysis illustrates that patients with HGBCL‐NOS represent a particularly difficult group to treat, even with CAR‐T therapy. We observed that one third of patients achieved a durable response; however, the overall results were less favourable, with lower overall response rate, overall survival and progression‐free survival as compared to published reports on LBCL.
Gene therapy pipelines for osteoarthritis: current innovations, operational challenges, and future directions
Peitso, Valtteri , Ng, Karman , Ellis, R. , Reginster, Jean‐Yves , Evans, Christopher H. , Mobasheri, Ali , Ellis, Ron

Mayo Clinic

Connective Tissue Research | July 4, 2025 | Volume: 66 | Issue: 5 | Pages: 458-465

10.1080/03008207.2025.2520319 | PMID 40611652 Get It

Ruxolitinib in Patients With Corticosteroid-Refractory or Corticosteroid-Dependent Chronic Graft-Versus-Host Disease: 3-Year Final Analysis of the Phase III REACH3 Study
Zeiser, Robert , Russo, Domenico , Ram, Ron , Hashmi, Shahrukh K. , Chakraverty, Ronjon , Middeke, Jan Moritz , Musso, Maurizio , Uzay, Ant , Langmuir, Peter, Burock, K., Gowda, Maanasa, Stefanelli, Tommaso , Lee, Stephanie J. , Hamad, Nada , Lee, Stephanie J , Teshima, Takanori , Locatelli, Franco , Giebel, Sebastian , Hamad, Nada

Mayo Clinic

Journal of Clinical Oncology | June 25, 2025 | Volume: 43 | Issue: 23 | Pages: 2566-2571

10.1200/jco-24-02477 | PMID 40561385 Get It

In REACH3 (ClinicalTrials.gov identifier: NCT03112603 ), ruxolitinib was investigated versus best available therapy (BAT) for 3 years in patients with steroid-refractory/dependent chronic graft-versus-host-disease (SR/D-cGVHD). Patients received ruxolitinib (10 mg twice daily) or BAT for 24 weeks; thereafter (weeks 24-156), patients continued randomized treatment, entered long-term survival follow-up, or crossed over from BAT to ruxolitinib. In 329 randomly assigned patients (ruxolitinib: 165; BAT: 164), the median failure-free survival (FFS) was 38.4 months for ruxolitinib versus 5.7 months for BAT (hazard ratio, 0.36 [95% CI, 0.27 to 0.49]). Median duration of response (DOR) was not reached for ruxolitinib versus 6.4 months for BAT. Ruxolitinib-treated patients had a higher probability of FFS (ruxolitinib: 56.5%; BAT: 18.2%) and maintaining a response (ruxolitinib: 59.6%; BAT: 26.7%) at 36 months. Median overall survival was not reached. Nonrelapse mortality and malignancy relapse/recurrence events were low. In 70 patients who crossed over to ruxolitinib, the overall response rate (50.0%) at week 24 and best overall response (81.4%) during the crossover period were consistent with the primary analysis of randomly assigned patients. No new safety signals were observed. Ruxolitinib provided longer FFS and DOR than BAT, demonstrating sustained efficacy and manageable safety over 3 years of follow-up in patients with SR/D-cGVHD.
International Registry of thyroid cancer in Latin American (CaTaLiNA): epidemiology, clinical and follow-up study protocol in Latin American countries during the period 2023–2028
Solís-Pazmiño, Paola , Solis-Pazmino, Paola , Ledesma, Tannya, Alvarado, Brayner Alejandro Ramírez, Rojas, Tatiana, Pazmino, Camila , Tite, Belen, Figueroa, Luis, Hernández, Víctor, Salazar, Jorge, García, Cristhian, Rosero, Daniela, Ruilova, Lisbeth, Imaicela, Luis , Abad, Hamilton, Palacios, Antonio Lozano, Zanella, Virgílio Gonzales , Nasseri, Yosef , Cohen, Jason , Brito, Juan P. , Ponce-Ponte, Oscar J., Ponce, Oscar J. , Lincango, Eddy, Rojas, Tatiana , Brito, Juan P , Ponce, Oscar Josue , Pilatuna, Eduardo A , Ron, Mario , Alvarado, Benjamin, Figueroa, Luis, Lincango-Naranjo, Eddy , Rosero, Daniela, López‐Guerrero, José Antonio , Paz‐Ibarra, José , Gonzalez, Camilo, Palacios, Antonio, Soto-Becerra, Percy

Mayo Clinic

BMJ Open | June 22, 2025 | Volume: 15 | Issue: 6 | Pages: e093471

10.1136/bmjopen-2024-093471 | PMID 40545306 Get It

Introduction Differentiated thyroid cancer (DTC) is the most common endocrine malignancy, with a high 5-year survival rate of approximately 98%. Despite advances in diagnosis and treatment, up to 20% of patients experience recurrence, adversely affecting their quality of life. Predictive models have been developed to assess recurrence risk and guide clinical decision-making, but these models often face limitations such as retrospective design, lack of diversity in study populations and absence of external validation. The primary aim is to externally validate existing predictive models for DTC recurrence using prospective data from a diverse Latin American cohort. The secondary aim is to explore opportunities for model recalibration to improve their performance in our population. Methods and analysis The CaTaLiNA study is a multicentre prospective observational study conducted across 10 hospitals in five Latin American countries, including Ecuador, Peru, Uruguay and Mexico. Patients aged 18 years or older receiving treatment for DTC, such as the first thyroid surgery, active surveillance or radiofrequency ablation will be included. Recruitment will occur from November 2023 to June 2025, with follow-up extending until June 2028. Data collection will include baseline clinical, surgical and histological characteristics, treatment details and follow-up outcomes. Statistical analysis will follow the Transparent Reporting of a multivariable prediction model for Individual Prognosis or Diagnosis guidelines, using imputation strategies for missing data and evaluating calibration and discrimination of the prediction models. Calibration measures include the ratio of expected and observed events, calibration slope and calibration plot, while discrimination will be assessed using the C-index and area under the receiver operating characteristic curve. Ethics and dissemination This study protocol was approved by Comité de Ética de Investigación en Seres Humanos de la Universidad San Francisco de Quito USFQ ‘CEISH-USFQ’ APO-010–2023-CEIHS-USFQ Oficio No. 161-2023-CA-23030M-CEISH-USFQ. Results will be disseminated via peer-reviewed publications.
Development of Rifampicin Eye Drops for the Treatment of Exudative Age-Related Macular Degeneration
Vailoces, Valory Anne Sarmiento , Tolentino, Andrew J., Arévalo, J. Fernando , Adelman, Ron A. , Bhisitkul, Robert B. , Diana, V., Nguyen, Quan Dong , Tolentino, Michael J. , Tanito, Masaki , Serizawa, Hiroaki, Arevalo, Jose Fernando

Mayo Clinic

Pharmaceuticals | May 2, 2025 | Volume: 18 | Issue: 5 | Pages: 655

10.3390/ph18050655 | PMID 40430474 Get It

Background/Objectives: Exudative age-related macular degeneration (AMD) is a disease of choroidal neovascularization that causes blindness. Current treatments to preserve vision in this prevalent and blinding condition are repeat intraocular injections of anti-vascular endothelial growth factor medicines for a patient’s lifetime to preserve and prevent vision loss leading to blindness. Rifampicin, a small-molecule antibiotic, has previously been reported to exhibit anti-angiogenic properties and a topical safety profile that is well-tolerated. Based on this evidence, we investigated the feasibility of formulating rifamycin as an ophthalmic drop capable of delivering therapeutic concentrations to the posterior segment of the eye. Methods: Inhibition of neovascularization by administration of rifampicin was analyzed in the rat oxygen-induced retinopathy (OIR) and mouse laser-induced choroidal neovascularization (CNV) models. Pharmacokinetic (PK) studies were conducted in mice, rats, and rabbits by dosing various formulations containing rifampicin, and the compound was quantified by LC/MS analysis. Results: Results from dose escalation studies in the mouse laser-induced CNV model suggested the minimum effective dose of rifampicin required for inhibiting neovascularization in subretinal tissues to be 0.7 mg/kg, which is substantially lower than the 20 mg/kg dosage approved for infectious disease treatments. The previous studies did not report the minimum effective dose in the anti-angiogenesis effects. The effective area under the concentration-time curve (AUC) in the sub-retina was evaluated as 0.27 h·ng/mg. In rabbits, rifampicin was delivered to the sub-retina by a single topical application of various formulations in a dose-dependent manner. The topical application of the formulations containing 1% rifampicin, which was well-tolerated in clinical trials previously reported for ocular trachoma, achieved subretinal delivery approximately 2–32 times greater than the effective AUC. Plasma exposure of the compound by the topical application was evaluated to range approximately 0.5–10 ng/mL. Conclusions: Rifampicin was delivered to the sub-retina in rabbits with an efficiency greater than the effective dose required for inhibiting neovascularization. Limited amounts of plasma exposure by the topical application were detected. These results suggested the therapeutic potential of the rifampicin formulations for the topical treatment of exudative macular degeneration.
Dilated Cardiomyopathy Evaluation with Imagenomics: Combining Multimodal Cardiovascular Imaging and Genetics
Galanti, Kristian , Dabbagh, Ghaith Sharaf , Ricci, Fabrizio , Gallina, Sabina, Giansante, Roberta , Jacob, Ron , Obeng‐Gyimah, Edmond, Prasad, Sanjay , Birnie, David H. , Landstrom, Andrew P. , Mohammed, Selma F. , Landstrom, Andrew P , Mohammed, Selma , Mohiddin, Saidi , Khanji, Mohammed Yunus , Chahal, Choudhary Anwar A , Sharaf Dabbagh, Ghaith , Ricci, Fabrizio , Gallina, Sabina , Jacob, Ron, Cooper, Leslie T. , Prasad, Sanjay K , Khanji, Mohammed Y , Chahal, C. Anwar A.

Mayo Clinic

ESC Heart Failure | April 25, 2025 | Volume: 12 | Issue: 4 | Pages: 2669-2690

10.1002/ehf2.15307 | PMID 40275589 Get It

Abstract Dilated cardiomyopathy (DCM) is a clinical diagnosis characterized by the presence of left ventricular dilatation and systolic dysfunction unexplained by abnormal loading conditions or coronary artery disease. However, a broad range of phenotypic manifestations, encompassing isolated scar, DCM with preserved ejection fraction, and overt DCM, should be regarded as a diagnostic classification representing a broad spectrum of underlying aetiologies, including both inherited and acquired heart muscle disorders. A multimodal non-invasive imaging approach is essential for accurate morpho-functional assessment of cardiac chambers and is key to establish the cardiac phenotype and to rule out an underlying ischaemic aetiology. Furthermore, advanced imaging techniques enable deep cardiovascular phenotyping and non-invasive tissue characterization. The aim of this review is to propose a systematic approach to the diagnosis of DCM, emphasizing the importance of genetics and clinical findings for a precise and practical clinical approach. Also, we strive to qualify the role of cardiac imaging in the diagnosis of DCM, particularly on the relevance of novel techniques and clinical utility of actionable parameters to improve current diagnostic schemes and risk stratification algorithms. We further elaborate on the role of cardiac imaging to deliver optimal guidance to aetiology-based therapeutic approaches, verification of treatment response and disease progression monitoring.
Early Postpartum Pelvic Floor Muscle Training With Transabdominal Ultrasound Imaging
Ron, Nicole J., Hill, Lauren H., Hahn, Kathleen M., Carlson, Anna M., Howden, Jenna G., Pennell, Taylor N., Rowenhorst, Rachel J., Ron, Eyal D. , Hill, Lauren H., Hahn, Kathleen M., Carlson, Anna M., Howden, Jenna G., Hollman, John H.

Mayo Clinic

Journal of Women's & Pelvic Health Physical Therapy | April 18, 2025 | Volume: 49 | Issue: 2 | Pages: 55-63

10.1097/jwh.0000000000000324 Get It

Purpose: This study examined if vertical bladder excursion during pelvic floor muscle (PFM) contraction, measured with transabdominal ultrasound (TAUS), improved following a single training session 0-5 days postpartum. It also assessed patient satisfaction with the training. Methods: 75 healthy, female volunteers within 0-5 days post-vaginal delivery were recruited during their inpatient postpartum stay. Participants completed one in-person session involving a standardized bladder filling protocol, TAUS imaging during PFM contractions, a PFM training session using TAUS as visual biofeedback, and a two-question post intervention survey. Vertical bladder base excursions were compared pre- and post- training between two groups: those whose bladder bases descended and those whose ascended during baseline contractions. A mixed model ANOVA with one between-group factor (baseline descenders vs. ascenders) and one within-group factor (pre- vs. post-training) analyzed the change in bladder lift. Patient satisfaction was assessed with Likert scales. Results: Mean vertical excursion increased from 0.12 cm (SD = 0.48) to 0.32 cm (SD = 0.33) post-training, which was statistically significant (p <.001, Cohens d = 0.767). Greater improvements were noted in those with a bladder base descent at baseline. All participants reported the experience to be helpful or very helpful and were satisfied or very satisfied. Discussion: Participants increased vertical bladder excursion during PFM contraction with TAUS biofeedback within a single session, especially those with baseline paradoxical bladder excursion and perineal trauma during delivery. Participants found the experience helpful and satisfying, suggesting TAUS biofeedback may be a useful tool in early postpartum PFM rehabilitation.
Dialysis Dependence in Standard versus Accelerated Initiation of KRT in AKI
McCoy, Ian E. , Ghamarian, Ehsan , Quenot, Jean‐Pierre , Zarbock, A., Bihorac, Azra , Khoo, Benjamin Zhi En , Gallagher, Martin , Du, Bin , Joannidis, Michael , Tolwani, Ashita , Investigators, For the STandard versus Accelerated initiation of Renal Replacement Therapy in AKI (STARRT-AKI), Guitton, Christophe , Bihari, Shailesh , Ghamarian, Ehsan , Bihorac, Azra , Khoo, Benjamin , Gallagher, Martin P , Du, Bin , Joannidis, Michael , Kashani, Kianoush B , Tolwani, Ashita , Bagshaw, Sean M , Wald, Ron , McCoy, Ian E , Liu, Kathleen D. , Kashani, Kianoush , Bagshaw, Sean M. , Investigators, For the STandard versus Accelerated initiation of Renal Replacement Therapy in AKI (STARRT-AKI)

Mayo Clinic

Clinical Journal of the American Society of Nephrology | March 11, 2025 | Volume: 20 | Issue: 5 | Pages: 601-607

10.2215/cjn.0000000672 | PMID 40232884 Get It

Key Points The Standard versus Accelerated Initiation of Renal Replacement Therapy in AKI trial found that starting dialysis earlier for AKI resulted in a 74% higher risk of still receiving dialysis at 90 days. Among patients who likely would have started dialysis under usual practice, the risks of dialysis dependence were similar. This suggests much of the risk observed may have been due to starting dialysis (versus never starting) rather than starting slightly earlier. Background The Standard versus Accelerated Initiation of Renal Replacement Therapy in AKI Trial showed that among critically ill patients with AKI, an accelerated KRT initiation strategy resulted in more KRT dependence at 90 days, as compared with a standard strategy. However, it is unclear whether this difference exists among participants who likely would have been treated with KRT in usual practice. Methods Secondary analysis of the Standard versus Accelerated Initiation of Renal Replacement Therapy in AKI randomized controlled trial, analyzing participants who received more than the median number of days of KRT, which served as a proxy for high probability of requiring KRT under usual practice. Two sensitivity analyses redefined the cohort as ( 1 ) those with ≥24 hours of oliguria who received KRT and ( 2 ) those who received any KRT. Using the same statistical approach as the original trial, we calculated unadjusted relative risks with 95% confidence intervals (CIs) for the exposure of randomized KRT initiation strategy (accelerated versus standard) on the outcome of KRT dependence at 90 days among survivors. Results Among the 1184 participants who received ≥6 days of KRT (670 and 514 in the accelerated and standard arms, respectively), baseline characteristics remained balanced between treatment arms. The relative risk of KRT dependence at 90 days was attenuated and nonsignificant: 1.21 (95% CI, 0.84 to 1.78), compared with 1.74 (95% CI, 1.24 to 2.43) in the overall trial. The results were similar in sensitivity analyses. Conclusions Among patients who likely would have been treated with KRT in usual practice, there was no significant difference in 90-day KRT dependence among survivors between those randomized to the accelerated and standard KRT initiation strategies. These results suggest that the harm of long-term KRT dependence may be largely due to KRT initiation (versus never initiation) rather than earlier initiation. Clinical Trial registry name and registration number: NCT02568722.